ATOSSA THERAPEUTICS, INC. Income Taxes Receivable, Current
ATOSSA THERAPEUTICS, INC. (ATOS) had Income Taxes Receivable, Current of $626.01 thousand as of 2018-06-30, per its 10-Q/A filed 2018-11-13.
Discontinued › Notes
us-gaap:IncomeTaxesReceivable · last filed 2018-11-13
- 2018-06-30: Income Taxes Receivable, Current $626.01K.
- 2018-03-31: Income Taxes Receivable, Current $395.87K.
- 2017-12-31: Income Taxes Receivable, Current $358.28K.
| Period end | Income Taxes Receivable, Current |
|---|---|
| 2018-06-30 | $626.01K 10-Q/A · filed 2018-11-13 |
| 2018-03-31 | $395.87K 10-Q · filed 2018-05-14 |
| 2017-12-31 | $358.28K 10-Q/A · filed 2018-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |